Merck to develop USD 1.3 billion research center in London by 2025

By Nikita Chaurasia  Date: 2020-08-19

Merck to develop USD 1.3 billion research center in London by 2025

America-based leading pharmaceutical company Merck & Co. Inc. (MSD) is reportedly moving ahead with its plans of building a research center in London. Sources close to the matter stated that the new facility, which will be known as London Discovery Research Centre, is valued at USD 1.3 billion and is estimated to be operational by the year 2025.

The project was initially announced in 2017 as a part of Merck’s initiative to support Britain post-Brexit, although it was delayed owing to the limitations in finding adequate space in the city, sources claimed. In addition to this, Merck intends to build its life sciences center near the Francis Crick Institute in the northern part of London.

However, the deal is yet to be finalized since it apparently requires the approval of London Borough of Camden. If sources are to be believed, work on the research center is anticipated to start late in 2021, with the facility providing over 120 jobs for technicians as well as researchers.

It appears that the site will be around 25,000 square meters and Merck intends to hire around 800 staff. Sources further stated that the research teams at the site will conduct early-stage diagnostics and majorly focus on age-related disorders.

MSD Managing Director for Ireland and UK, David Peacock, was reported saying that the company views the United Kingdom as a leader in developing science, which is primarily driven by the country’s long-term focus on developing a robust R&D infrastructure.

It is to be noted that Merck had entered a five-year joint venture agreement with Crick Institute to promote research & development in neuroscience. Although Merck’s research projects were conducted independently, the team was completely integrated into the scientific community of Crick Institute.

In fact, research teams from Merck and Crick collaborated in August 2019, in an effort to analyze the cause of Motore Neurone Disease, which was the first combined project since the initial five-year partnership.

Source Credits –

https://www.biospace.com/article/merck-to-build-1-31-billion-research-hub-in-london/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

India’s Gennova Biopharmaceutical working on Omicron-specific vaccine

India’s Gennova Biopharmaceutical working on Omicron-specific vaccine

By Nikita Chaurasia

Gennova's potential mRNA vaccine is currently undergoing Phase II and Phase III trials. If approved for a EUA, it would be India’s first mRNA COVID-19 vaccine. Gennova Biopharmaceutical, a subsidiary of Pune-based drugmaker Emcure, is...

Recykal secures USD 22 Mn in a fundraise led by Morgan Stanley India

Recykal secures USD 22 Mn in a fundraise led by Morgan Stanley India

By Nikita Chaurasia

Recykal, a B2B waste management and recycling marketplace head-quartered in Hyderabad, has reportedly raised USD 22 million in funding from Morgan Stanley India. According to the company, existing investors including Circulate Capital, Arun Venkatac...

Reliance buys controlling stake in NYC hotel in its hospitality push

Reliance buys controlling stake in NYC hotel in its hospitality push

By Nikita Chaurasia

Reliance Industries Ltd. is reportedly planning to acquire a controlling stake in New York's five-star Mandarin Oriental Hotel for around USD 100 million. The company stated in a stock exchange filing that its industrial investments subsidiary, ...

India inoculates 3.8 million teens over fears of third COVID-19 wave

India inoculates 3.8 million teens over fears of third COVID-19 wave

By Nikita Chaurasia

India has reportedly vaccinated over 3.8 million teens aged between 15-18 years as of 3rd January in an effort to boost its inoculation drive to protect the large young population before the onslaught of a possible third wave of coronavirus infection...

Apple on track to become the world’s first USD 3 trillion company

Apple on track to become the world’s first USD 3 trillion company

By Nikita Chaurasia

Tech giant Apple Inc. has once again become the world’s most valuable company as it is just a hair's breadth away from a market capitalization of USD 3 trillion. On Monday, the iPhone maker’s shares slid a little over 2% to USD 175.7...